Venture Life Group PLC Grant of Options and PDMR Dealing (3405C)
22 Februar 2022 - 8:00AM
UK Regulatory
TIDMVLG
RNS Number : 3405C
Venture Life Group PLC
22 February 2022
22(nd) February 2022
VENTURE LIFE GROUP PLC
("Venture Life" "VLG" or the "Group")
Grant of Options
Venture Life (AIM: VLG), a leader in developing, manufacturing
and commercialising products for the self-care market, has, on the
recommendation of the Company's Remuneration Committee, issued
options over 300,000 ordinary shares of 0.3 pence each in the
Company to Daniel Wells, Chief Financial Officer. Mr Wells has been
awarded 300,000 unapproved share options under the Company's Share
Option Plan, with an exercise price of 43.0 pence per share, being
the closing mid-market price on 21(st) February 2022. The vesting
of these options is subject to continuing employment and the
satisfaction of performance conditions based on profitability and
TSR targets. The options become exercisable on 31(st) March
2025.
As a results of the issue of these share options, Daniel Wells
holds options over a total of 445,349 ordinary shares in the
Company.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
+44 (0) 20 7397
Cenkos Securities plc (Nomad and Joint Broker) 8900
Michael Johnson/Russell Kerr (Sales)
Stephen Keys/Camilla Hume (Corporate Finance)
+44 (0) 20 7496
Singer Capital markets (Joint Broker) 3000
Jonathan Dighe (Sales)
Shaun Dobson/Alaina Wong (Corporate Finance)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company
focused on developing, manufacturing and commercialising products
for the global self-care market. With operations in the UK, Italy,
The Netherlands and Sweden, the Group's product portfolio includes
some key products such as the UltraDEX and Dentyl oral care product
ranges, the Balance Active range in the area of women's intimate
healthcare, the Lift and Glucogel product ranges for hypoglycaemia,
products for fungal infections and proctology, and dermo-cosmetics
for addressing the signs of ageing. Its products are sold in over
90 countries worldwide.
The products, which are typically recommended by pharmacists or
healthcare practitioners, are available primarily through
pharmacies and grocery multiples. In the UK and The Netherlands
these are supplied direct by the company to retailers, elsewhere
they are supplied by the Group's international distribution
partners.
Through its two Development & Manufacturing operations in
Italy and Sweden, the Group also provides development and
manufacturing services to companies in the medical devices and
cosmetic sectors.
The Company makes the following disclosures in accordance with
article 19(3) of the Market Abuse Regulation:
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Daniel Wells
-------------------------- ----------------------------------------
2 Reason for the notification
--------------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------- ----------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
--------------------------------------------------------------------
a) Name Venture Life Group plc
-------------------------- ----------------------------------------
b) LEI 213800S8CZUPLAB2KC70
-------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
--------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.3p each in Venture
financial instrument, Life Group plc
type of instrument
Identification code GB00BFPM8908
-------------------------- ----------------------------------------
b) Nature of the transaction Grant of new options for ordinary
shares
-------------------------- ----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
Exercise Price
-
43.0p per option 300,000
----------
-------------------------- ----------------------------------------
d) Aggregated information n/a
- Aggregated volume
- Price
-------------------------- ----------------------------------------
e) Date of the transaction 22(nd) February 2022
-------------------------- ----------------------------------------
f) Place of the transaction n/a
-------------------------- ----------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUAOBRUKUUUAR
(END) Dow Jones Newswires
February 22, 2022 02:00 ET (07:00 GMT)
Venture Life (LSE:VLG)
Historical Stock Chart
Von Jan 2025 bis Feb 2025
Venture Life (LSE:VLG)
Historical Stock Chart
Von Feb 2024 bis Feb 2025
